Literature DB >> 26666933

Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam.

Jean-Marie Pagès1, Sabine Peslier2, Thomas A Keating3, Jean-Philippe Lavigne4, Wright W Nichols3.   

Abstract

This study examined the activity of the novel antimicrobial combination ceftazidime-avibactam against Enterobacteriaceae exhibiting different outer membrane permeability profiles, specifically with or without porins and with or without expression of the main efflux pump (AcrAB-TolC). The addition of the outer membrane permeabilizer polymyxin B nonapeptide increased the antibacterial activities of avibactam alone, ceftazidime alone, and ceftazidime-avibactam against the characterized clinical isolates of Escherichia coli, Enterobacter aerogenes, and Klebsiella pneumoniae. This enhancement of activities was mainly due to increased passive penetration of compounds since inhibition of efflux by the addition of phenylalanine-arginine β-naphthylamide affected the MICs minimally. OmpF (OmpK35) or OmpC (OmpK36) pores were not the major route by which avibactam crossed the outer membranes of E. coli and K. pneumoniae. In contrast, Omp35 and Omp36 allowed diffusion of avibactam across the outer membrane of E. aerogenes, although other diffusion channels for avibactam were also present in that species. It was clear that outer membrane permeability and outer membrane pore-forming proteins play a key role in the activity of ceftazidime-avibactam. Nevertheless, the MICs of ceftazidime-avibactam (with 4 mg/liter avibactam) against the ceftazidime-resistant clinical isolates of the three species of Enterobacteriaceae studied were ≤ 8 mg/liter, regardless of outer membrane permeability changes resulting from an absence of defined porin proteins or upregulation of efflux.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26666933      PMCID: PMC4775948          DOI: 10.1128/AAC.01585-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  Antibiotic resistance-the need for global solutions.

Authors:  Ramanan Laxminarayan; Adriano Duse; Chand Wattal; Anita K M Zaidi; Heiman F L Wertheim; Nithima Sumpradit; Erika Vlieghe; Gabriel Levy Hara; Ian M Gould; Herman Goossens; Christina Greko; Anthony D So; Maryam Bigdeli; Göran Tomson; Will Woodhouse; Eva Ombaka; Arturo Quizhpe Peralta; Farah Naz Qamar; Fatima Mir; Sam Kariuki; Zulfiqar A Bhutta; Anthony Coates; Richard Bergstrom; Gerard D Wright; Eric D Brown; Otto Cars
Journal:  Lancet Infect Dis       Date:  2013-11-17       Impact factor: 25.071

2.  Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.

Authors:  Robert K Flamm; Gregory G Stone; Helio S Sader; Ronald N Jones; Wright W Nichols
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

3.  In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.

Authors:  Ayumi Yoshizumi; Yoshikazu Ishii; Kotaro Aoki; Raymond Testa; Wright W Nichols; Kazuhiro Tateda
Journal:  J Infect Chemother       Date:  2014-10-25       Impact factor: 2.211

4.  In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.

Authors:  Henry Li; Mark Estabrook; George A Jacoby; Wright W Nichols; Raymond T Testa; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

5.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

6.  French regional surveillance program of carbapenemase-producing Gram-negative bacilli: results from a 2-year period.

Authors:  A Pantel; A Boutet-Dubois; H Jean-Pierre; H Marchandin; A Sotto; J-P Lavigne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-19       Impact factor: 3.267

Review 7.  New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors:  Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

8.  Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.

Authors:  Mariana Castanheira; Sarah E Farrell; Kevin M Krause; Ronald N Jones; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

9.  In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

Authors:  Thérèse Stachyra; Premavathy Levasseur; Marie-Claude Péchereau; Anne-Marie Girard; Monique Claudon; Christine Miossec; Michael T Black
Journal:  J Antimicrob Chemother       Date:  2009-06-02       Impact factor: 5.790

10.  How beta-lactam antibiotics enter bacteria: a dialogue with the porins.

Authors:  Chloë E James; Kozhinjampara R Mahendran; Alexander Molitor; Jean-Michel Bolla; Andrey N Bessonov; Mathias Winterhalter; Jean-Marie Pagès
Journal:  PLoS One       Date:  2009-05-12       Impact factor: 3.240

View more
  36 in total

Review 1.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

2.  Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.

Authors:  Romney M Humphries; Peera Hemarajata
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

Authors:  Boudewijn L M de Jonge; James A Karlowsky; Krystyna M Kazmierczak; Douglas J Biedenbach; Daniel F Sahm; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 5.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Authors:  Stephanie Ho; Lynn Nguyen; Trang Trinh; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2019-09-09       Impact factor: 3.725

Review 6.  Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.

Authors:  Matt Shirley
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 7.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

Review 8.  New β-Lactamase Inhibitors in the Clinic.

Authors:  Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

9.  In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

10.  Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.

Authors:  Ghady Haidar; Ammar Alkroud; Shaoji Cheng; Travis M Churilla; Bryce M Churilla; Ryan K Shields; Yohei Doi; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.